-
Clarivate (CLVT) Tops Q4 EPS by 4c; Offers Guidance
-
Goldman Sachs Downgrades Clarivate Plc (CLVT) to Neutral
-
Clarivate (CLVT) Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
-
Morgan Stanley Downgrades Clarivate Plc (CLVT) to Underweight
-
Clarivate launches AI assistant for regulatory compliance teams
-
Clarivate launches AI-powered patent monitoring software
-
Clarivate (CLVT) files for 245.08M share offering by selling stockholders
-
Clarivate (CLVT) Tops Q3 EPS by 2c ; Offers Guidance
-
Clarivate launches AI patent analysis tools for Innography platform
-
RBC Capital on Clarivate Plc (CLVT): 'VCP Progress to Drive ACV and Subscription Growth'
-
Wolfe Research Starts Clarivate Plc (CLVT) at Peerperform
-
Clarivate launches AI regulatory assistant in beta for Cortellis suite
-
Clarivate (CLVT) Misses Q2 EPS by 28c; reaffirms guidance
-
Jefferies Downgrades Clarivate Plc (CLVT) to Hold
-
Stifel Reiterates Buy Rating on Clarivate Plc (CLVT)
-
Clarivate (CLVT) Tops Q1 EPS by 2c, provides guidance
-
Clarivate (CLVT) Tops Q4 EPS by 1c, provides guidance
-
Clarivate (CLVT) Announces $500M Share Buyback
-
Clarivate (CLVT) Reports In-Line Q3 EPS
-
Clarivate (CLVT) to Sell Scholarone to TSCP
-
Clarivate (CLVT) Appoints Melanie Margolin as Chief Administrative and Legal Officer
-
Clarivate Plc (CLVT) PT Lowered to $7 at RBC Capital
-
Clarivate (CLVT) Tops Q2 EPS by 2c, reaffirms guidance
-
Clarivate (CLVT) Appoints Matti Shem Tov as CEO
-
Clarivate (CLVT) Announces Retirement of Director Richard Roedel
-
Clarivate (CLVT) Acquires Rowan TELS
-
Clarivate (CLVT) Reveals First Year of Unitary Patent Court Litigation Activity

